Tradestie Institutional Equity Comparison Engine
IDNA vs GNOM โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
IDNA Overall Edge
IDNA Captures Institutional Edge (2โ0 Pillars ยท 2โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to iShares Genomics Immunology and Healthcare ETF (IDNA) driven by superior Momentum & Technical, Options & Structure. Fundamentally, IDNA trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus GNOM at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, IDNA sits in UNCLASSIFIED (20th %ile IV; Dealer Gamma Walls on Pro) against GNOM sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
IDNA N/M vs GNOM N/M Fwd P/E
Growth & Margin Winner
Tie
Op Margin N/A vs N/A ยท YoY N/A vs N/A
Momentum & Technical Winner
IDNA
1Y +52.0% vs +37.1% ยท 52W Pos 74% vs 54%
Options & Structure Winner
IDNA
UNCLASSIFIED (20th %ile IV) vs UNCLASSIFIED (100th %ile IV)
IDNA
NYSE Arca
iShares Genomics Immunology and Healthcare ETF
Institutional Equity
$39.25
-2.12% 1D
Market Cap
N/A
1M Return
-3.18%
1Y Return
+51.96%
Forward P/E
N/M
Unified AI Score
41.7 / 100
SELL
Tech 28.0
Fund 33.0
Flow 50.0
Mom 21.8
GNOM
NASDAQ
Global X Genomics & Biotechnology ETF
Institutional Equity
$59.16
-4.07% 1D
Market Cap
N/A
1M Return
-8.0%
1Y Return
+37.11%
Forward P/E
N/M
Unified AI Score
45.1 / 100
HOLD
Tech 30.0
Fund 42.0
Flow 50.0
Mom 64.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
IDNA +51.96%
GNOM +37.11%
Spread: +14.85 pp (IDNA Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
IDNA TTM Op. Margin: N/A
GNOM TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IDNA vs GNOM. Trailing 12-month operating profitability (IDNA N/A vs GNOM N/A) and valuation multiples (IDNA N/M vs GNOM N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | IDNA | GNOM | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | N/A | Larger Scale | Tie |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | N/A | N/A | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | N/A | N/A | Higher Margin | Tie |
| Net Profit Margin Profitability | N/A | N/A | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | N/A | N/A | Higher ROE | Tie |
| 52-Week Range Position Momentum | 74% ($25โ$44) | 54% ($41โ$74) | Stronger Trend | IDNA |
| Beta / 30D Volatility Risk Regime | 1.17ฮฒ ยท 44% Vol | 1.49ฮฒ ยท 54% Vol | Lower Realized Risk | IDNA |
| Unified Institutional Score Composite Signal | 41.7 / 100 (SELL) | 45.1 / 100 (HOLD) | Higher Composite | GNOM |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full IDNA vs GNOM Buy Guide
IDNA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
20th %ile
IV Regime
Compressed (<25th %ile)
GNOM
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
100th %ile
IV Regime
Extreme (>80th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither IDNA nor GNOM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.